ArticleJournal of thoracic disease2025
Association of peripheral-blood neutrophil-to-lymphocyte ratio with
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and monocyte-to-lymphocyte ratio as prognostic indicators inFrontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The infection of Methods: We retrospectively reviewed medical records of all consecutive patients with solid tumors and a proven diagnosis of PJP according to the European Organization for Research and Treatment of Cancer (EORTC) consensus definitions. Patients were randomly grouped into a discovery cohort and a validation cohort in a 2:1 ratio. Propensity score matching was performed in a 1:2 ratio between patients with PJP and those without PJP. Demographic and clinical data were collected, which included malignancy types, baseline NLR, chest imaging, coexisting pulmonary disease, and treatment regimens. The receiver operating characteristic (ROC) curve was used to determine the optimal cutoff value of NLR for analyzing risk of PJP. Multivariate logistic analysis was performed to identify the risk factors of PJP. Results: A total of 249 patients were included, of whom 83 had PJP infection and 166 did not. A total of 157 (63.1%) patients were aged 65 years or older, 73.5% of participants were male, and 37.3% were never-smokers. Patients with PJP had a higher NLR level than those without PJP (P<0.001). The optimal threshold of NLR to predict PJP was 6.22. Multivariate analysis revealed independent associations with higher NLR (odds ratio: 4.96; 95% confidence interval: 1.82-13.50; P=0.002) and PJP after adjustment for age, sex, and smoking status. The incidence of PJP in the high-NLR subgroup (NLR ≥6.22) was significantly higher than that in the low-NLR subgroup (NLR Conclusions: Among patients with solid tumors, a baseline feature of high NLR (≥6.22) was independently associated with an increased risk of PJP development. Furthermore, the NLR demonstrates potential utility in assessing immune status. Therefore, clinicians should consider initiating PJP prophylaxis earlier or performing earlier PJP screening in patients with solid tumors and elevated peripheral blood NLR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.